Scott Bernstein, MD
Internal Medicine · Pomona, NYNPI 1689601817
Payments from drug & device makers
Across 181 payments — averaging $22.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Lilly USA, LLC$271
- Novo Nordisk$243
- Johnson & Johnson$224
- Boehringer Ingelheim$216
- Amgen$213
- plus $2K from 26 others
What the payments were for
- Travel & lodging$84020%
- Food & beverage$3,29079%
- Gifts$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 10 | $1,050 |
| Lilly USA, LLC | 15 | $271 |
| Novo Nordisk | 17 | $243 |
| Johnson & Johnson | 13 | $224 |
| Boehringer Ingelheim | 12 | $216 |
| Amgen | 10 | $213 |
| AstraZeneca | 13 | $177 |
| Pfizer | 10 | $160 |
| GSK | 9 | $154 |
| Atricure, Inc. | 1 | $139 |
| Merck | 11 | $138 |
| Teva Pharmaceuticals USA, Inc. | 10 | $123 |
| Angiodynamics, Inc. | 1 | $117 |
| Amarin Pharma, Inc. | 6 | $102 |
| Philips North America LLC | 3 | $87 |
| E.r. Squibb & Sons, L.L.C. | 5 | $86 |
| Boston Scientific | 3 | $79 |
| Bayer | 3 | $63 |
| Astellas Pharma US Inc | 3 | $63 |
| Regeneron Healthcare Solutions, Inc. | 3 | $62 |
| AbbVie(2 entities) | 4 | $57 |
| Kowa Pharmaceuticals America, Inc. | 3 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $55 |
| Novartis | 4 | $53 |
| W. L. Gore & Associates, Inc. | 1 | $34 |
| Sanofi Pasteur Inc. | 2 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Circassia Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $15 |
| Shionogi Inc | 1 | $15 |
| Abbott | 1 | $13 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,142 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 186 | $214,027 |
| JardianceEmpagliflozin | 119 | $143,482 |
| EliquisApixaban | 129 | $121,647 |
| JanuviaSitagliptin Phosphate | 79 | $106,905 |
| XareltoRivaroxaban | 69 | $74,681 |
| TrulicityDulaglutide | 31 | $52,710 |
| FarxigaDapagliflozin Propanediol | 31 | $49,697 |
| MounjaroTirzepatide | 30 | $35,407 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $25,184 |
| TradjentaLinagliptin | 17 | $24,723 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $14,355 |
| KeppraLevetiracetam | 24 | $12,332 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 44 | $12,328 |
| MyrbetriqMirabegron | 16 | $11,430 |
| Atorvastatin Calcium | 936 | $9,436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $243 | $214,027186 claims |
| Boehringer IngelheimJardiance, Tradjenta | $216 | $168,205136 claims |
| PfizerEliquis, Abrysvo, Dilantin | $160 | $131,525166 claims |
| MerckJanuvia | $138 | $106,90579 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $271 | $88,11761 claims |
| Johnson & JohnsonXarelto | $224 | $74,68169 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Arexvy, Shingrix | $154 | $61,252142 claims |
| AstraZenecaFarxiga, Brilinta | $177 | $56,49446 claims |
| Astellas Pharma US IncMyrbetriq | $63 | $11,43016 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $12 | $6,503386 claims |
| AbbVieSynthroid | $57 | $6,064146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Pomona
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.